Association of P53 gene expression alteration among breast cancer patients in Erbil province

Year 2017, , 205 - 209, 30.06.2017

Rozhgar A. Khailany , Mustafa S. Al-attar Amer A. Hasan

https://doi.org/10.17826/cutf.322799

Abstract

Purpose: Breast cancer is the most lethal disease and the leading cause of cancer death among women in worldwide. P53, a tumor-suppressor gene, is best known to be associated with human cancers and more than 50% of human cancers contain P53 alteration, which is guardian of the genome. In the current study, we aimed to evaluate mRNA expression level of P53 gene among breast cancer patients in Erbil province.

Material and Methods: Thirty four pairs breast cancer tissues and their corresponding non-cancerous breast tissues that were grouped according to the types of breast cancer and clinical features of patients were examined by semi- quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) technique.

Results: Expression quantity of P53 gene in breast cancer samples was significantly increased (Up-regulated) according to expression quantity of normal samples.

Conclusion: The over-expression of p53 gene might be a potential molecular genetics marker for breast cancer diagnosis in women; further analysis are mandatory to a better understand and confirm our preliminary findings.

Keywords

Breast cancer, P53, expression analysis, semi-quantitative RT-PCR

Erbil’de meme kanseri hastalarında P53 geni ekspresyonundaki değişikliklerin ilişkisi

Abstract

Amaç: Meme kanseri, dünyadaki kadınlarda ölümcül en büyük hastalık ve kanser ölümünün önde gelen nedenidir. P53, tümör baskılayıcı bir gen, insan kanserleri ile ilişkili olduğu bilinen ve insan kanserlerinin% 50'sinden fazlası,esas görevi genomun koruyucusu olan P53 geninin alterasyonunu içerir. Bu çalışmada, Erbil ilindeki meme kanseri hastalarında P53 geninin mRNA ekspresyon düzeyini değerlendirmeyi amaçladık.

Gereç ve Yöntem: Otuz dört hastaya ait meme kanseri dokusu ve yine bu hastalara ait kanserli olmayan göğüs dokuları meme kanseri tiplerine ve hastaların klinik özelliklerine göre gruplandırıldı ve yarı kantitatif ters transkriptaz polimeraz zincir reaksiyonu (qRT-PCR) tekniği ile incelendi.

Bulgular: Normal örneklerin ekspresyon miktarına göre meme kanseri örneklerinde P53 geninin ekspresyon miktarı önemli ölçüde arttmıştır.(upregüle).

Sonuç: P53 geninin aşırı ekspresyonu kadınlarda meme kanseri tanısı için potansiyel bir moleküler genetik belirteç olabilir; ön bulgularımızı daha iyi anlamak ve doğrulamak için daha fazla analiz yapılması zorunludur.

Keywords

Meme kanseri, P53, ekspresyon analizi, yarı kantitatif RT-PCR

References

• 1. Bunz F. Principle of Cancer Genetics. Maryland, Springer Netherland, 2008
• 2. Meshram II, Hiwarkar PA, Kulkarni PN. Reproductive risk factors for breast cancer: a case control study. Online Journal of Health and Allied Sciences. 2009;8:5-10.
• 3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
• 4. Gerdes A, Cruger G, Thomassen M, Kruse A. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet. 2006;69:171-8.
• 5. Rozhgar AK, Ari Q.N, Nadhum JI. PCR-based quantification of exon 21 in BRCA2 gene in Breast cancer patients in Erbil province. ZANCO Journal of Pure and Applied Sciences. 2016;28:94-7.
• 6. Morgan J, Gladson JE, Rau KS. Position paper of the American Council on Science and Health on risk factors for breast cancer: established, speculated, and unsupported. Breast J. 1998;4:177–97.
• 7. George P. P53 How crucial is its role in cancer?. Int J Curr Pharm Res. 2011;3:19- 25.
• 8. Cassidy J, Bisset D, Spence RA, Payne A. Oncology. 2nd ed. New York, Oxford University Press, 2006.
• 9. Liu Y, Bodmer W. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006;103:976-81.
• 10. Ismaiel NJ, Mohammed RA, Hidayat HJ. Gene expression of P53 and adipoq as diagnostic markers for colorectal cancer. Cukurova Med J. 2016;41:217-23.
• 11. Nejad A, Yaghoobi M. Mutation Analysis of TP53 Tumor suppressor gene in colorectal cancer in patients from Iran (Kerman Province). Iran J Basic Med Sci. 2012;15:683-90.
• 12. Ismaiel NJ, Mohammed RA, Hidayat HJ. Molecular genetics of renal cell carcinoma: polybromo 1 and set domain containing 2 genes. Cukurova Med J. 2016;41:105-11.
• 13. Khailany RA, Igci M, Bayraktar E, Erturhan S, Karakok M, Arslan A. VHL, PBRM1 and SETD2 genes in kidney cancer: A molecular investigation. International Journal of Medical, Health, Biomedical and Pharmaceutical Engineering. 2015;9:389-92.
• 14. Marc L, Robert-Alain T and Guy L. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293–325.
• 15. Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594-604.
• 16. Attardi LD, Jacks T. The role of p53 in tumor suppression: lessons from mouse models. Cell Mol Life Sci. 1999;55:48-63.
• 17. Chungyeul KM, Yusuke TM, Soonmyung PM. Gene-expression-based prognostic and predictive markers for breast cancer - A primer for practicing pathologists. Arch Pathol Lab Med. 2009;133:855-9.
• 18. Pavel RJ, Marilie DG, Yu-Jing ZA, Mary BT, Hanina HE, Lorenzo MF et al. Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009;13:3847-57.
• 19. Enxiang Z, Na H, Min S, Baiping W, Jianlin Z. Systematic analysis of the p53 related microRNAs in breast cancer revealing their essential roles in the cell cycle. Oncol Lett. 2015;10:3488-94.